#gsk — Public Fediverse posts

GSK stock edges higher as HIV and vaccine franchises support revenue growth

GSK (ISIN GB0009252882) stock is influenced in 2026 by the performance of its core HIV and vaccines franchises,…
#EuropeSays #Britain #Europe #EU #GSK #GB0009252882
https://www.europesays.com/britain/90623/

https://www.europesays.com/britain/90623/ GSK stock edges higher as HIV and vaccine franchises support revenue growth #GB0009252882 #GSK

GSK stock trades steadily as vaccine and specialty medicines growth supports earnings

GSK stock offers investors exposure to a large global pharmaceuticals and vaccines business whose recent earnings have been…
#EuropeSays #Britain #Europe #EU #GSK #GB0009252882
https://www.europesays.com/britain/90170/

https://www.europesays.com/britain/90170/ GSK stock trades steadily as vaccine and specialty medicines growth supports earnings #GB0009252882 #GSK

GSK Stock And UK Blue Chips Tied To Infrastructure Spending And Fiscal Confidence

With UK government debt above 95% of GDP and investors closely watching John Healey’s fiscal plans, bond market…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/89821/

https://www.europesays.com/britain/89821/ GSK Stock And UK Blue Chips Tied To Infrastructure Spending And Fiscal Confidence #GSK

GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes — BigGo Finance

GSK had never won FDA approval for a lung cancer drug — not in decades of trying. Then,…
#EuropeSays #Britain #Europe #EU #GSK #AxiomBiosciences #FDA #FierceBiotech #HongKongExchange #Jideytro #MarissaRusso #nasdaq #Nuvalent #TheTopLine #U.S.HouseofRepresentatives
https://www.europesays.com/britain/89781/

https://www.europesays.com/britain/89781/ GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes — BigGo Finance #AxiomBiosciences #FDA #FierceBiotech #GSK #HongKongExchange #Jideytro #MarissaRusso #nasdaq #Nuvalent #TheTopLine #USHouseOfRepresentatives

GSK admits 70,759 new shares to London market | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #admissiontotrading #blocklisting #Form6-K #GSKplc #LondonStockExchange #ordinaryshares #ShareSavePlan2022
https://www.europesays.com/britain/89766/

https://www.europesays.com/britain/89766/ GSK admits 70,759 new shares to London market | GSK SEC Filing #AdmissionToTrading #BlockListing #Form6K #GSK #GSKPlc #LondonStockExchange #OrdinaryShares #ShareSavePlan2022

GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
#EuropeSays #Britain #Europe #EU #GSK #GSKstock #stockportfolio
https://www.europesays.com/britain/89749/

https://www.europesays.com/britain/89749/ GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval #GSK #GSKStock #StockPortfolio

GSK executive acquires 9.4 notional ADS in plan | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #ADS #AmericanDepositaryShares #executivesupplementalsavingsplan #Form6-K #GSKplc #insidertransaction #MayaMartinez-Davis #NYSE
https://www.europesays.com/britain/89735/

https://www.europesays.com/britain/89735/ GSK executive acquires 9.4 notional ADS in plan | GSK SEC Filing #ADS #AmericanDepositaryShares #ExecutiveSupplementalSavingsPlan #Form6K #GSK #GSKPlc #InsiderTransaction #MayaMartinezDavis #NYSE

https://www.europesays.com/britain/?p=89719 Weekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data #acquisition #AdenoAssociatedVirus #DidNotMeetEndpoint #DiscontinueTheStudy #European UnionApproval #FDA #FDA510(k)Clearance #FirstLungCancerTherapy #GeneTherapy #GSK #HNSCC #Keytruda #Layoff #merge #MultipleMyeloma #Obesity #PDUFA #ReusableSpO2ClipSensor #Type2Daibetes

https://www.europesays.com/britain/?p=89701 GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada #ClinicalTrials&MedicalDiscoveries #GlaxoSmithKlineInc #GSK #HealthCare&Hospitals #InfectionControl #InternationalMedicalApproval #MedicalPharmaceuticals #Pharmaceuticals

https://www.europesays.com/britain/89681/ Shell & GSK: Stock market week ahead – 27-31 July #GSK #StandardArticle #Stocks&Shares #TheStockMarketWeekAhead

Rx Rundown: Samsung Biologics, Dimension, GSK and more

Deals: Samsung Biologics to buy Swiss PolyPeptide Group in a $1.8 billion deal. Tempus bought out cancer genomics…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/89605/

https://www.europesays.com/britain/89605/ Rx Rundown: Samsung Biologics, Dimension, GSK and more #GSK

GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
#EuropeSays #Britain #Europe #EU #GSK #non-smallcelllungcancer #shareprice #totalshareholderreturn
https://www.europesays.com/britain/89589/

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada

Prefilled syringe offers healthcare professionals a convenient administration option New presentation will begin rolling out across Canada in…
#EuropeSays #Britain #Europe #EU #GSK #AdvisoryCommitteeonImmunizationPractices #Canada #CardiovascularDisease #chronicconditions #healthcareprofessionals #Prefilledsyringe #presentation #shingles #vaccineadministration #ZosterVaccine
https://www.europesays.com/britain/89567/

https://www.europesays.com/britain/89567/ GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada #AdvisoryCommitteeOnImmunizationPractices #Canada #CardiovascularDisease #ChronicConditions #GSK #HealthcareProfessionals #PrefilledSyringe #presentation #shingles #VaccineAdministration #ZosterVaccine

‘I had dreams’: How HIV care has evolved across a generation

In 2025, almost 41 million people were living with HIV worldwide, according to UNAIDS, with over half living…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/89539/

https://www.europesays.com/britain/89539/ ‘I had dreams’: How HIV care has evolved across a generation #GSK

GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
#EuropeSays #Britain #Europe #EU #GSK #GSKstock #stockportfolio
https://www.europesays.com/britain/89514/

https://www.europesays.com/britain/89514/ GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval #GSK #GSKStock #StockPortfolio

How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And Wider Risk Signals

Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
#EuropeSays #Britain #Europe #EU #GSK #HowConsumerStocksAreReadingTodayThroughGSK(LSE:GSK)AndWiderRiskSignals
https://www.europesays.com/britain/89441/

https://www.europesays.com/britain/89441/ How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And Wider Risk Signals #GSK #HowConsumerStocksAreReadingTodayThroughGSK(LSE:GSK)AndWiderRiskSignals

Samsung Biologics First-Half Operating Profit Tops ₩1 Trillion; Annual Revenue of ₩5 Trillion Within Reach — BigGo Finance

Samsung Biologics (207940) has surpassed ₩1 trillion (approximately $678.2 million) in half-year operating profit for the first time…
#EuropeSays #Korea #KR #SamsungBiologics #BioCampus3 #Celltrion #GLP-1 #GSK #JohnRim #Netherlandssalesoffice #peptide #Plant5 #PolyPeptideGroup #Rockvilleproductionfacility #Samsung
https://www.europesays.com/korea/97114/

How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And London Risk Signals

Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/89349/

https://www.europesays.com/britain/89349/ How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And London Risk Signals #GSK

GSK shelves cough drug acquired in $2B deal

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
#EuropeSays #Britain #Europe #EU #GSK #chroniccough #coughmedicine #irritablebowelsyndrome #TreviTherapeutics
https://www.europesays.com/britain/89320/

https://www.europesays.com/britain/89320/ GSK shelves cough drug acquired in $2B deal #ChronicCough #CoughMedicine #GSK #IrritableBowelSyndrome #TreviTherapeutics

Is GSK (LSE:GSK) Undervalued Following Jideytro Approval?

The latest move in GSK (LSE:GSK) stock interest is tied to the early US FDA approval of Jideytro…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/89306/

https://www.europesays.com/britain/89306/ Is GSK (LSE:GSK) Undervalued Following Jideytro Approval? #GSK

GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
#EuropeSays #Britain #Europe #EU #GSK #Bexsero #Jemperli #Jideytro #Lungcancer #meningococcaldisease #Oncology #rectalcancer
https://www.europesays.com/britain/89247/

https://www.europesays.com/britain/89247/ GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance #Bexsero #GSK #Jemperli #Jideytro #LungCancer #MeningococcalDisease #Oncology #RectalCancer

GSK FDA Approves Jideytro; 44% Response Rate

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or…
#EuropeSays #Britain #Europe #EU #GSK #FDAapproval #GSKticker #Jideytro #Lungcancer #Oncology #ROS1-positiveNSCLC #zidesamtinib
https://www.europesays.com/britain/89049/

https://www.europesays.com/britain/89049/ GSK FDA Approves Jideytro; 44% Response Rate #FDAApproval #GSK #GSKTicker #Jideytro #LungCancer #Oncology #ROS1PositiveNSCLC #zidesamtinib

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards…
#EuropeSays #Britain #Europe #EU #GSK #acquisition #brainmetastases #kinaseinhibitor #Lungcancer #Nuvalent #resistancemutations #USFoodandDrugAdministration
https://www.europesays.com/britain/89008/

https://www.europesays.com/britain/89008/ GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet #acquisition #BrainMetastases #GSK #KinaseInhibitor #LungCancer #Nuvalent #ResistanceMutations #USFoodAndDrugAdministration

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

GSK plc GSK announced that the FDA has approved Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung…
#EuropeSays #Britain #Europe #EU #GSK #FDA #GSKplc #Jideytro #NeurocrineBiosciences #non-smallcelllungcancer #ZacksInvestmentResearch #ZacksRank
https://www.europesays.com/britain/88972/

https://www.europesays.com/britain/88972/ GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC #FDA #GSK #GSKPlc #Jideytro #NeurocrineBiosciences #NonSmallCellLungCancer #ZacksInvestmentResearch #ZacksRank

Will GSK’s Specialty Medicines Boost Q2 Revenue Growth?

GSK plc’s GSK Specialty Medicines business segment spans four core areas: Respiratory, Immunology & Inflammation (RI&I), Oncology and…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #GSKstock #Oncology #Oncologysales #patientdemand #specialty #ZacksInvestmentResearch
https://www.europesays.com/britain/88940/

https://www.europesays.com/britain/88940/ Will GSK’s Specialty Medicines Boost Q2 Revenue Growth? #GSK #GSKPlc #GSKStock #Oncology #OncologySales #PatientDemand #specialty #ZacksInvestmentResearch

GSK wins FDA nod for Jideytro lung cancer drug | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #ARROS-1clinicaltrial #FDAapproval #GSK6-K #Jideytro #Nuvalentacquisition #OncologyDrug #ROS1-positiveNSCLC #zidesamtinib
https://www.europesays.com/britain/88610/

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or…
#EuropeSays #Britain #Europe #EU #GSK #Biotechnology #ClinicalTrials&MedicalDiscoveries #FDAapproval #GSKplc #HealthCare&Hospitals #MedicalEquipment #MedicalPharmaceuticals #Pharmaceuticals
https://www.europesays.com/britain/88598/

https://www.europesays.com/britain/88610/ GSK wins FDA nod for Jideytro lung cancer drug | GSK SEC Filing #ARROS1ClinicalTrial #FDAApproval #GSK #GSK6K #Jideytro #NuvalentAcquisition #OncologyDrug #ROS1PositiveNSCLC #zidesamtinib

https://www.europesays.com/britain/88598/ Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer #Biotechnology #ClinicalTrials&MedicalDiscoveries #FDAApproval #GSK #GSKPlc #HealthCare&Hospitals #MedicalEquipment #MedicalPharmaceuticals #Pharmaceuticals

$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval

A drug included in one of the pharmaceutical industry’s largest acquisitions this year is starting to paying dividends…
#EuropeSays #Britain #Europe #EU #GSK #biopharmanl #Cancer #ClinicalTrials #FDA #Lungcancer #non-smallcelllungcancer #Nuvalent #Spotlight-payeropp
https://www.europesays.com/britain/88582/